Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Accentia Biopharmace (ABPI)

Accentia Biopharmace (ABPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Accentia Biopharmace 324 SOUTH HYDE PARK AVE SUITE 350 TAMPA FL 33606

www.accentia.net P: 813-864-2554

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of late-stage disruptive clinical products. Accentia has a portfolio of currently marketed respiratory products and a pipeline of products in clinical development. The company's lead respiratory product candidate is SinuNase, which is under clinical development to treat chronic sinusitis. SinuNase is a novel application and formulation of a known anti-fungal exclusively licensed from the Mayo Foundation for Medical Education and Research. The product has been Fast Tracked by the FDA and the Company has commenced a Phase three clinical trial. The Company's other lead product is BiovaxID, a patient-specific anti-cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma. BiovaxID, which is being developed by Accentia's subsidiary Biovest International, Inc.

Key Statistics

Overview:

Market Capitalization, $K 10
Shares Outstanding, K 89,760
Annual Sales, $ 4,050 K
Annual Net Income, $ -4,320 K
60-Month Beta -0.47
% of Insider Shareholders 22.84%
% of Institutional Shareholders 0.01%

Growth:

1-Year Return -95.65%
3-Year Return -99.83%
5-Year Return -99.99%
5-Year Revenue Growth -77.84%
5-Year Earnings Growth -94.44%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 12/31/69
Earnings Per Share ttm 0.00
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ABPI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -106.67%
Debt/Equity 0.00
Price/Sales 0.43
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.00
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar